title: Maternal glucocorticoid treatment programs HPA regulation in adult offspring: sex-specific effects.
abstract: Pregnant guinea pigs were treated with dexamethasone (1 mg/kg) or vehicle on days 40--41, days 50--51, and days 60--61 of gestation. Adult offspring were split into two groups. Group 1 guinea pigs were catheterized, and the hypothalamo-pituitary-adrenal (HPA) axis was tested in basal and activated states. Group 2 guinea pigs were euthanized with no further manipulation. In male offspring, prenatal dexamethasone exposure resulted in a significant reduction in brain-to-body weight ratio. Dexamethasone-exposed male offspring exhibited reduced basal and activated plasma cortisol levels, which was associated with elevated hippocampal mineralocorticoid receptor (MR) mRNA and increased plasma testosterone. In females exposed to glucocorticoids in utero, basal and stimulated plasma cortisol levels were higher in the follicular and early luteal phases of the cycle, but this effect was reversed in the late luteal phase, indicating a significant interaction of sex steroids. In female offspring (at estrus), glucocorticoid receptor mRNA levels were lower in the paraventricular nucleus and pars distalis but higher in the hippocampus in animals exposed to dexamethasone in utero. Hippocampal MR mRNA levels were significantly lower (approximately 50%) than in controls. In conclusion, repeated antenatal glucocorticoid treatment programs HPA function in a sex-specific manner, and these changes are associated with modification of corticosteroid receptor expression in the adult brain and pituitary.
authors: Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
authors: L
authors: L
authors: Liu
authors: A
authors: A
authors: Li
authors: S G
authors: SG
authors: Matthews
mesh_terms: D000375:Aging / Q000502:physiology; D000818:Animals; D000831:Animals, Newborn / Q000033:anatomy & histology / Q000235:genetics; D001794:Blood Pressure; D001835:Body Weight / Q000187:drug effects; D003346:Corticotropin-Releasing Hormone / Q000235:genetics; D003907:Dexamethasone / Q000494:pharmacology*; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology*; D006168:Guinea Pigs; D006728:Hormones / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000254:growth & development / Q000502:physiology; D007031:Hypothalamus / Q000378:metabolism; D008032:Limbic System / Q000378:metabolism; D008297:Male; D010902:Pituitary Gland / Q000378:metabolism; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000254:growth & development / Q000502:physiology; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects*; D011297:Prenatal Exposure Delayed Effects; D012333:RNA, Messenger / Q000378:metabolism; D011965:Receptors, Glucocorticoid / Q000235:genetics; D018161:Receptors, Mineralocorticoid / Q000235:genetics; D012149:Restraint, Physical; D012727:Sex Characteristics; D013268:Stimulation, Chemical
chemical_list: D005938:Glucocorticoids; D006728:Hormones; D012333:RNA, Messenger; D011965:Receptors, Glucocorticoid; D018161:Receptors, Mineralocorticoid; D003907:Dexamethasone; D003346:Corticotropin-Releasing Hormone